Interestingly, in the syngeneic CT26 colon cancer allograft mouse model we observed additional involvement of IFNγ signaling and leukocyte activation-migration in the tumor immune micro-environment, which could not be addressed in the in vitro treatment setup (Figure 6B). The gene discussed is IFNG; the disease is neoplasm.